261 related articles for article (PubMed ID: 26821931)
1. Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program.
Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; DeMarco D; Zhang J; Mei J; Hou J
BMC Cancer; 2016 Jan; 16():46. PubMed ID: 26821931
[TBL] [Abstract][Full Text] [Related]
2. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Richardson PG; Siegel DS; Vij R; Hofmeister CC; Baz R; Jagannath S; Chen C; Lonial S; Jakubowiak A; Bahlis N; Song K; Belch A; Raje N; Shustik C; Lentzsch S; Lacy M; Mikhael J; Matous J; Vesole D; Chen M; Zaki MH; Jacques C; Yu Z; Anderson KC
Blood; 2014 Mar; 123(12):1826-32. PubMed ID: 24421329
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
Baertsch MA; Schlenzka J; Mai EK; Merz M; Hillengaß J; Raab MS; Hose D; Wuchter P; Ho AD; Jauch A; Hielscher T; Kunz C; Luntz S; Klein S; Schmidt-Wolf IG; Goerner M; Schmidt-Hieber M; Reimer P; Graeven U; Fenk R; Salwender H; Scheid C; Nogai A; Haenel M; Lindemann HW; Martin H; Noppeney R; Weisel K; Goldschmidt H
BMC Cancer; 2016 Apr; 16():290. PubMed ID: 27114074
[TBL] [Abstract][Full Text] [Related]
4. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Martino EA; Palmieri S; Galli M; Derudas D; Mina R; Della Pepa R; Zambello R; Vigna E; Bruzzese A; Mangiacavalli S; Zamagni E; Califano C; Musso M; Conticello C; Cerchione C; Mele G; Di Renzo N; Offidani M; Tarantini G; Casaluci GM; Rago A; Ria R; Uccello G; Barilà G; Palumbo G; Pettine L; Vincelli ID; Brunori M; Accardi F; Amico V; Amendola A; Fontana R; Bongarzoni V; Rossini B; Cotzia E; Gozzetti A; Rizzi R; Sgherza N; Reddiconto G; Maroccia A; Franceschini L; Bertuglia G; Nappi D; Barbieri E; Gamberi B; Petrucci MT; Di Raimondo F; Neri A; Morabito F; Musto P; Gentile M
Hematol Oncol; 2024 Jul; 42(4):e3290. PubMed ID: 38818978
[TBL] [Abstract][Full Text] [Related]
5. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.
Perrot A; Delimpasi S; Spanoudakis E; Frølund U; Belotti A; Oriol A; Moreau P; McFadden I; Xia Q; Arora M; Dimopoulos MA
Leuk Lymphoma; 2024 Jun; 65(6):833-842. PubMed ID: 38497533
[TBL] [Abstract][Full Text] [Related]
6. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi T; Spencer A; Hájek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG
Br J Haematol; 2017 Aug; 178(4):571-582. PubMed ID: 28485007
[TBL] [Abstract][Full Text] [Related]
7. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Lu J; Lee JH; Huang SY; Qiu L; Lee JJ; Liu T; Yoon SS; Kim K; Shen ZX; Eom HS; Chen WM; Min CK; Kim HJ; Lee JO; Kwak JY; Yiu W; Chen G; Ervin-Haynes A; Hulin C; Facon T
Br J Haematol; 2017 Mar; 176(5):743-749. PubMed ID: 28106903
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
Zinzani PL; Vose JM; Czuczman MS; Reeder CB; Haioun C; Polikoff J; Tilly H; Zhang L; Prandi K; Li J; Witzig TE
Ann Oncol; 2013 Nov; 24(11):2892-7. PubMed ID: 24030098
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.
Zhou H; Wang Y; Chen J; He A; Jin J; Lu Q; Zhao Y; Li J; Hou M; Su L; Lai X; Wang W; Liu L; Ma Y; Gao D; Lai W; Zhou X; Jing H; Zhang J; Yang W; Ran X; Lin C; Hao J; Xiao T; Huang Z; Zhu Z; Wang Q; Fang B; Wang B; Song Y; Cai Z; Liu B; Zhu Y; Yang X; Kang X; Li J; Chen W
Ann Hematol; 2024 Mar; 103(3):855-868. PubMed ID: 38112795
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Dimopoulos MA; Swern AS; Li JS; Hussein M; Weiss L; Nagarwala Y; Baz R
Blood Cancer J; 2014 Nov; 4(11):e257. PubMed ID: 25382609
[TBL] [Abstract][Full Text] [Related]
11. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Richardson PG; Oriol A; Larocca A; Bladé J; Cavo M; Rodriguez-Otero P; Leleu X; Nadeem O; Hiemenz JW; Hassoun H; Touzeau C; Alegre A; Paner A; Maisel C; Mazumder A; Raptis A; Moreb JS; Anderson KC; Laubach JP; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;
J Clin Oncol; 2021 Mar; 39(7):757-767. PubMed ID: 33296242
[TBL] [Abstract][Full Text] [Related]
12. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.
Hinsley S; Walker K; Sherratt D; Bailey L; Reed S; Flanagan L; McKee S; Brudenell Straw F; Dawkins B; Meads D; Auner HW; Kaiser MF; Cook M; Brown S; Cook G;
Trials; 2020 Oct; 21(1):826. PubMed ID: 33008427
[TBL] [Abstract][Full Text] [Related]
13. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
Xia Z; Leng Y; Fang B; Liang Y; Li W; Fu C; Yang L; Ke X; Jiang H; Weng J; Liu L; Zhao Y; Zhang X; Huang Z; Liu A; Shi Q; Gao Y; Chen X; Pan L; Cai Z; Wang Z; Wang Y; Fan Y; Hou M; Ma Y; Hu J; Liu J; Zhou J; Zhang X; Meng H; Lu X; Li F; Ren H; Huang B; Shao Z; Zhou H; Hu Y; Yang S; Zheng X; Wei P; Pang H; Yu W; Liu Y; Gao S; Yan L; Ma Y; Jing H; Du J; Ling W; Zhang J; Sui W; Wang F; Li X; Chen W
BMC Cancer; 2023 Oct; 23(1):980. PubMed ID: 37838670
[TBL] [Abstract][Full Text] [Related]
14. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Dimopoulos MA; Lonial S; White D; Moreau P; Palumbo A; San-Miguel J; Shpilberg O; Anderson K; Grosicki S; Spicka I; Walter-Croneck A; Magen H; Mateos MV; Belch A; Reece D; Beksac M; Bleickardt E; Poulart V; Sheng J; Sy O; Katz J; Singhal A; Richardson P
Br J Haematol; 2017 Sep; 178(6):896-905. PubMed ID: 28677826
[TBL] [Abstract][Full Text] [Related]
15. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
Richardson PG; Hofmeister CC; Rosenbaum CA; Htut M; Vesole DH; Berdeja JG; Liedtke M; Chari A; Smith SD; Lebovic D; Raje N; Byrne C; Liao E; Gupta N; Bacco AD; Estevam J; Berg D; Baz R
Br J Haematol; 2018 Jul; 182(2):231-244. PubMed ID: 29938772
[TBL] [Abstract][Full Text] [Related]
16. Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.
Ailawadhi S; Sexton R; Lentzsch S; Abidi MH; Voorhees PM; Cohen AD; Rohren EM; Heitner S; Kelly K; Mackler NJ; Baer DM; Hoering A; Durie B; Orlowski RZ
Clin Cancer Res; 2020 Aug; 26(15):3969-3978. PubMed ID: 32299820
[TBL] [Abstract][Full Text] [Related]
17. Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Luo Y; Li C; Niu Y; Wu S; Tian J; Hu Z; He J; Zhang Z; Liu H; Li Y; Wang T; Fang Y
Expert Rev Hematol; 2024; 17(4-5):127-134. PubMed ID: 38421372
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Lund J; Gruber A; Lauri B; Duru AD; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Carlsson C; Waage A; Gimsing P; Vangsted AJ; Frølund U; Holmberg E; Gahrton G; Alici E; Hardling M; Mellqvist UH; Nahi H
Cancer Med; 2018 Jun; 7(6):2256-2268. PubMed ID: 29673108
[TBL] [Abstract][Full Text] [Related]
19. Target trial emulation of carfilzomib safety among patients with relapsed/refractory multiple myeloma using a nationwide observational data in Korea.
Lee HK; Jang HY; Kim IW; Oh JM
J Cancer Res Clin Oncol; 2024 May; 150(5):266. PubMed ID: 38769166
[TBL] [Abstract][Full Text] [Related]
20. Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye.
Tekinalp A; Gedük A; Akdeniz A; Terzi Demirsoy E; Gürsoy V; Aslaner Ak M; Bağcı M; Seçilmiş S; Keklik Karadağ F; Oruç Uysal A; Doğan A; Demircioğlu S; Erol HA; Aslan C; Özkalemkaş F; Ertop Ş; Dağlı M; Dal MS; Saydam G; Merter M; Ural C; Çeneli Ö
Turk J Haematol; 2023 Dec; 40(4):242-250. PubMed ID: 37961952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
